BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Madhvi A, Hingane S, Srivastav R, Joshi N, Subramani C, Muthumohan R, Khasa R, Varshney S, Kalia M, Vrati S, Surjit M, Ranjith-Kumar CT. A screen for novel hepatitis C virus RdRp inhibitor identifies a broad-spectrum antiviral compound. Sci Rep 2017;7:5816. [PMID: 28725041 DOI: 10.1038/s41598-017-04449-3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
Number Citing Articles
1 Khalid H, Landry KB, Ijaz B, Ashfaq UA, Ahmed M, Kanwal A, Froeyen M, Mirza MU. Discovery of novel Hepatitis C virus inhibitor targeting multiple allosteric sites of NS5B polymerase. Infect Genet Evol 2020;84:104371. [PMID: 32485331 DOI: 10.1016/j.meegid.2020.104371] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
2 Dighe SN, Ekwudu O, Dua K, Chellappan DK, Katavic PL, Collet TA. Recent update on anti-dengue drug discovery. Eur J Med Chem 2019;176:431-55. [PMID: 31128447 DOI: 10.1016/j.ejmech.2019.05.010] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 7.0] [Reference Citation Analysis]
3 Pallerla SR, Harms D, Johne R, Todt D, Steinmann E, Schemmerer M, Wenzel JJ, Hofmann J, Shih JWK, Wedemeyer H, Bock CT, Velavan TP. Hepatitis E Virus Infection: Circulation, Molecular Epidemiology, and Impact on Global Health. Pathogens. 2020;9. [PMID: 33092306 DOI: 10.3390/pathogens9100856] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 4.5] [Reference Citation Analysis]
4 Rumlová M, Ruml T. In vitro methods for testing antiviral drugs. Biotechnol Adv 2018;36:557-76. [PMID: 29292156 DOI: 10.1016/j.biotechadv.2017.12.016] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
5 Hingane S, Joshi N, Surjit M, Ranjith-Kumar CT. Hepatitis E Virus ORF2 Inhibits RIG-I Mediated Interferon Response. Front Microbiol 2020;11:656. [PMID: 32351484 DOI: 10.3389/fmicb.2020.00656] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
6 Liu W, Jiang X, Liu Y, Ma Q. Bioinformatics Analysis of Quantitative PCR and Reverse Transcription PCR in Detecting HCV RNA. CBIO 2019;14:400-5. [DOI: 10.2174/1574893613666180703103328] [Cited by in Crossref: 4] [Article Influence: 1.3] [Reference Citation Analysis]
7 Kinast V, Burkard TL, Todt D, Steinmann E. Hepatitis E Virus Drug Development. Viruses. 2019;11. [PMID: 31141919 DOI: 10.3390/v11060485] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 4.0] [Reference Citation Analysis]
8 Gupta J, Irfan M, Ramgir N, Muthe KP, Debnath AK, Ansari S, Gandhi J, Ranjith-kumar CT, Surjit M. Antiviral Activity of Zinc Oxide Nanoparticles and Tetrapods Against the Hepatitis E and Hepatitis C Viruses. Front Microbiol 2022;13:881595. [DOI: 10.3389/fmicb.2022.881595] [Reference Citation Analysis]
9 Venkatesan A, Prabhu Dass J F. Review on chemogenomic approaches towards hepatitis C viral targets. J Cell Biochem 2019;120:12167-81. [PMID: 30887580 DOI: 10.1002/jcb.28581] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
10 Sáez-Álvarez Y, Arias A, Del Águila C, Agudo R. Development of a fluorescence-based method for the rapid determination of Zika virus polymerase activity and the screening of antiviral drugs. Sci Rep 2019;9:5397. [PMID: 30932009 DOI: 10.1038/s41598-019-41998-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
11 Anang S, Kaushik N, Surjit M. Recent Advances Towards the Development of a Potent Antiviral Against the Hepatitis E Virus. J Clin Transl Hepatol 2018;6:310-6. [PMID: 30271744 DOI: 10.14218/JCTH.2018.00005] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]